[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509238":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":39,"locations":45,"responsibleParty":291,"collaborators":293,"id":296,"slug":297,"hasResults":298,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":30,"eligibilityCriteria":302,"healthyVolunteers":298,"sex":303,"minAge":304,"maxAge":30,"enrollmentInfo":305,"targetDuration":30,"studyType":308,"phases":309,"briefSummary":312,"conditions":313,"keywords":321,"overallStatus":62,"whyStopped":30,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":345},{"fullName":5,"class":6},"Hummingbird Bioscience","INDUSTRY",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","Participants receive HMBD-001 with docetaxel. This treatment arm is closed to recruitment.",[13,14],"Drug: HMBD-001","Drug: Docetaxel",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm B","Participants receive HMBD-001 with docetaxel plus cetuximab. This treatment arm is closed to recruitment.",[13,14,19],"Drug: Cetuximab",{"label":21,"type":10,"description":22,"interventionNames":23},"Arm C","Participants receive HMBD-001 with cetuximab",[13,19],[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","HMBD-001","HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly",[9,16,21],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Docetaxel","Docetaxel 75 mg\u002Fm\\^2 or 60 mg\u002Fm IV once every 3 weeks",[9,16],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Cetuximab","Cetuximab 250 mg\u002Fm\\^2 weekly, with or without 400 mg\u002Fm\\^2 IV loading dose at C1D1",[16,21],[40],{"name":41,"role":42,"phone":43,"phoneExt":30,"email":44},"Kevin Heller, Dr","CONTACT","+65 6978 9377","k.heller@hummingbirdbio.com",[46,60,76,86,99,113,127,136,150,164,177,186,199,211,223,232,244,258,270,282],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":30},"GenesisCare North Shore","WITHDRAWN","Sydney","New South Wales","2065","Australia","AU",{"type":55,"coordinates":56},"Point",[57,58],151.20732,-33.86785,{"lat":58,"lon":57},{"facility":61,"status":62,"city":63,"state":50,"zip":64,"country":52,"countryCode":53,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Westmead Hospital","RECRUITING","Westmead","2145",{"type":55,"coordinates":66},[67,68],150.98768,-33.80383,{"lat":68,"lon":67},[71,73],{"name":72,"role":42,"phone":30,"phoneExt":30,"email":30},"Rosemary Habib",{"name":74,"role":75,"phone":30,"phoneExt":30,"email":30},"Rosemary Dr Habib","PRINCIPAL_INVESTIGATOR",{"facility":77,"status":48,"city":78,"state":79,"zip":80,"country":52,"countryCode":53,"cosmosGeoPoint":81,"geoPoint":85,"contacts":30},"ICON Cancer Centre South Brisbane","Brisbane","Queensland","4101",{"type":55,"coordinates":82},[83,84],153.02809,-27.46794,{"lat":84,"lon":83},{"facility":87,"status":62,"city":88,"state":79,"zip":89,"country":52,"countryCode":53,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Greenslopes Private Hospital","Greenslopes","4120",{"type":55,"coordinates":91},[92,93],153.04951,-27.50815,{"lat":93,"lon":92},[96,98],{"name":97,"role":42,"phone":30,"phoneExt":30,"email":30},"Rahul Ladwa",{"name":97,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":100,"status":62,"city":101,"state":102,"zip":103,"country":52,"countryCode":53,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Southern Oncology Clinical Research Unit","Adelaide","South Australia","5042",{"type":55,"coordinates":105},[106,107],138.59863,-34.92866,{"lat":107,"lon":106},[110,112],{"name":111,"role":42,"phone":30,"phoneExt":30,"email":30},"Ganessan Kichenadasse",{"name":111,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":114,"status":62,"city":115,"state":116,"zip":30,"country":52,"countryCode":53,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Peninsula & South Eastern Haematology and Oncology Group","Frankston","Victoria",{"type":55,"coordinates":118},[119,120],145.12291,-38.14458,{"lat":120,"lon":119},[123,125],{"name":124,"role":42,"phone":30,"phoneExt":30,"email":30},"Vinod Ganju",{"name":126,"role":75,"phone":30,"phoneExt":30,"email":30},"Vinod Prof Ganju",{"facility":128,"status":48,"city":129,"state":116,"zip":130,"country":52,"countryCode":53,"cosmosGeoPoint":131,"geoPoint":135,"contacts":30},"Cabrini Health","Malvern","3144",{"type":55,"coordinates":132},[133,134],145.02811,-37.86259,{"lat":134,"lon":133},{"facility":137,"status":62,"city":138,"state":139,"zip":140,"country":52,"countryCode":53,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Linear Clinical Research","Perth","Western Australia","6009",{"type":55,"coordinates":142},[143,144],115.8614,-31.95224,{"lat":144,"lon":143},[147,149],{"name":148,"role":42,"phone":30,"phoneExt":30,"email":30},"Samantha Bowyer",{"name":148,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":151,"status":62,"city":152,"state":30,"zip":30,"country":153,"countryCode":154,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"The Institute of Oncology, ARENSIA Exploratory Medicine Phase I Unit","Chisinau","Moldova","MD",{"type":55,"coordinates":156},[157,158],28.85938,47.00902,{"lat":158,"lon":157},[161,163],{"name":162,"role":42,"phone":30,"phoneExt":30,"email":30},"Iurie Bulat",{"name":162,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":165,"status":62,"city":166,"state":30,"zip":30,"country":166,"countryCode":167,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"National Cancer Centre Singapore","Singapore","SG",{"type":55,"coordinates":169},[170,171],103.85007,1.28967,{"lat":171,"lon":170},[174,176],{"name":175,"role":42,"phone":30,"phoneExt":30,"email":30},"Aaron Tan",{"name":175,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":178,"status":62,"city":166,"state":30,"zip":30,"country":166,"countryCode":167,"cosmosGeoPoint":179,"geoPoint":181,"contacts":182},"Tan Tock Seng Hospital",{"type":55,"coordinates":180},[170,171],{"lat":171,"lon":170},[183,185],{"name":184,"role":42,"phone":30,"phoneExt":30,"email":30},"Jens Samol",{"name":184,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":187,"status":62,"city":188,"state":30,"zip":30,"country":189,"countryCode":30,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Chungbuk National University Hospital","Cheongju-si","South Korea",{"type":55,"coordinates":191},[192,193],127.48972,36.63722,{"lat":193,"lon":192},[196,198],{"name":197,"role":42,"phone":30,"phoneExt":30,"email":30},"Ki Hyeong Lee",{"name":197,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":200,"status":62,"city":201,"state":30,"zip":30,"country":189,"countryCode":30,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"CHA Bundang Medical Center, CHA University","Seongnam-si",{"type":55,"coordinates":203},[204,205],127.13778,37.43861,{"lat":205,"lon":204},[208,210],{"name":209,"role":42,"phone":30,"phoneExt":30,"email":30},"Joo-Hang Kim",{"name":209,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":212,"status":62,"city":213,"state":30,"zip":30,"country":189,"countryCode":30,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"Korea University Anam Hospital","Seoul",{"type":55,"coordinates":215},[216,217],126.9784,37.566,{"lat":217,"lon":216},[220,222],{"name":221,"role":42,"phone":30,"phoneExt":30,"email":30},"Yoon Ji Choi",{"name":221,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":224,"status":62,"city":213,"state":30,"zip":30,"country":189,"countryCode":30,"cosmosGeoPoint":225,"geoPoint":227,"contacts":228},"Severance Hospital",{"type":55,"coordinates":226},[216,217],{"lat":217,"lon":216},[229,231],{"name":230,"role":42,"phone":30,"phoneExt":30,"email":30},"Hye Ryun Kim",{"name":230,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":233,"status":62,"city":234,"state":30,"zip":30,"country":189,"countryCode":30,"cosmosGeoPoint":235,"geoPoint":239,"contacts":240},"The Catholic University of Korea St. Vincent's Hospital","Suwon",{"type":55,"coordinates":236},[237,238],127.00889,37.29111,{"lat":238,"lon":237},[241,243],{"name":242,"role":42,"phone":30,"phoneExt":30,"email":30},"Byoung Yong Shim",{"name":242,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":245,"status":62,"city":246,"state":30,"zip":30,"country":247,"countryCode":248,"cosmosGeoPoint":249,"geoPoint":253,"contacts":254},"Kaohsiung Medical University Chung-Ho Memorial Hospital","Kaohsiung City","Taiwan","TW",{"type":55,"coordinates":250},[251,252],120.31333,22.61626,{"lat":252,"lon":251},[255,257],{"name":256,"role":42,"phone":30,"phoneExt":30,"email":30},"Jen-Yu Hung",{"name":256,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":259,"status":62,"city":260,"state":30,"zip":30,"country":247,"countryCode":248,"cosmosGeoPoint":261,"geoPoint":265,"contacts":266},"National Cheng Kung University Hospital","Tainan",{"type":55,"coordinates":262},[263,264],120.21333,22.99083,{"lat":264,"lon":263},[267,269],{"name":268,"role":42,"phone":30,"phoneExt":30,"email":30},"Chun-Hui Lee",{"name":268,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":271,"status":62,"city":272,"state":30,"zip":30,"country":247,"countryCode":248,"cosmosGeoPoint":273,"geoPoint":277,"contacts":278},"Taipei Medical University - Shuang Ho Hospital","Taipei",{"type":55,"coordinates":274},[275,276],121.52639,25.05306,{"lat":276,"lon":275},[279,281],{"name":280,"role":42,"phone":30,"phoneExt":30,"email":30},"Wei-Hong Cheng",{"name":280,"role":75,"phone":30,"phoneExt":30,"email":30},{"facility":283,"status":62,"city":272,"state":30,"zip":30,"country":247,"countryCode":248,"cosmosGeoPoint":284,"geoPoint":286,"contacts":287},"Taipei Veterans General Hospital",{"type":55,"coordinates":285},[275,276],{"lat":276,"lon":275},[288,290],{"name":289,"role":42,"phone":30,"phoneExt":30,"email":30},"Yung-Hung Lo",{"name":289,"role":75,"phone":30,"phoneExt":30,"email":30},{"type":292,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[294],{"name":295,"class":6},"Merck KGaA, Darmstadt, Germany","100509238","phase-1-a-phase-ibii-study-of-an-anti-her3-antibody-hmbd-001-with-cetuximab---docetaxel-in-advanced-squamous-cell-cancers-100509238",false,"NCT05910827","A Phase Ib\u002FII Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +\u002F- Docetaxel in Advanced Squamous Cell Cancers","A Phase Ib\u002FII Study to Evaluate HMBD-001 in Combination With Cetuximab, With or Without Docetaxel in Participants With Advanced Squamous Cell Carcinomas","Inclusion Criteria:\n\n* Ability to understand and be willing to sign an informed consent form\n\n  * Males and females aged over 18 years (or having reached the age of majority according to local laws if the age of majority is \\> 18 years of age)\n  * Eastern Cooperative Oncology Group (ECOG) status of 0 to 1\n  * Arm B only: Locally advanced or metastatic squamous non-small cell lung cancer for which all available standard of care treatment options have been exhausted or refused and for which at least one lesion is measurable\n  * Arm C only: Advanced or metastatic sqNSCLC, HNSCC, ESCC, CSCC, cervical SCC, NPC and other SCCs with at least one prior line of systemic therapy,\n  * Have an estimated life expectancy of at least 3 months\n  * Participants must be willing to provide a fresh tumor biopsy sample\n  * Have adequate organ function\n  * Females must be non-pregnant and non-lactating, willing to use a highly effective method of contraception from screening until study completion or be either surgically sterile or post-menopausal\n  * Males must be surgically sterile, abstinent, or if engaged in sexual relations with a woman of child-bearing potential, the participant and his partner must be surgically sterile or using an acceptable, highly effective contraceptive method from screening until study completion\n\nExclusion Criteria:\n\n* Prior treatment with HMBD-001, docetaxel, cetuximab or any other agent that targets Epidermal Growth Factor Receptor (EGFR) or HER3, including pan-HER inhibitors. Prior treatment with docetaxel is allowed for Arm C\n\n  * Receipt of prior targeted therapy, including but not limited to those targeting EGFR activating mutations, ALK fusions, ROS rearrangements, RET fusions or mutations, BRAF V600E mutation, MET exon 14 skipping mutation, and\u002For KRAS G12C mutation\n  * Persistent clinically significant toxicities (Grade ≥2) from previous anti-cancer therapy except for Grade \\>2 toxicities that are considered unlikely to put the participant at an increased risk of treatment-related toxicity and\u002For impact the study results e.g., alopecia\n  * Most recent anti-cancer therapy including radiotherapy at least 4 weeks, or nitrosourea or mitomycin 3 at least 6 weeks, or 5 half-lives whichever is shorter prior to starting the assigned study treatment\n  * Symptomatic primary Central Nervous System (CNS) cancer or metastases unless the symptoms are stable for at least 28 days prior to the first dose of the study drug and any symptoms have returned to baseline\n  * Evidence of abnormal cardiac function\n  * History of uncontrolled allergic reactions and\u002For known expected hypersensitivity to the study drugs used in the treatment arm to which the participant is to be enrolled into\n  * Any other known active malignancy except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer\n  * Any uncontrolled illness or significant uncontrolled condition(s) requiring systemic treatment\n  * Known Human Immunodeficiency Virus (HIV) infection\n  * Active hepatitis B or hepatitis C infection\n  * Pregnant or breast feeding\n  * COVID 19 infection within 3 months prior to the first dose of the study drug\n  * COVID 19 vaccination within 14 days prior to the first dose of the study drug\n  * Treatment with strong inhibitors or inducers of CYP3A4","ALL","18 Years",{"count":306,"type":307},398,"ESTIMATED","INTERVENTIONAL",[310,311],"PHASE1","PHASE2","This is a Phase Ib\u002FII multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers",[314,315,316,317,318,319,320],"Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","Advanced Head and Neck Squamous Cell Carcinoma","Advanced Esophageal Squamous Cell Carcinoma","Cervical Squamous Cell Carcinoma","Advanced Cutaneous Squamous Cell Carcinoma","Nasopharyngeal Cancinoma (NPC)","Squamous Cell Carcinoma",[322,323,324,325,326,327,328,32,36,329,330,331,332,333,334,335],"NSCLC","Non-small Cell Lung Cancer","sqNSCLC","Lung","Squamous","HER3","ErbB3","cervical squamous cell carcinoma","HNSCC","CSCC","ESCC","advanced squamous cell cancer","NPC","SCC","2026-05-24",{"date":338,"type":339},"2026-05-27","ACTUAL",{"date":341,"type":339},"2024-02-05",{"date":343,"type":307},"2027-12",{"name":5,"class":6},20]